Tocilizumab may induce secondary hypogammaglobulinaemia. A retrospective case series of 42 patients

Francisco Vílchez-Oya; Ana Pros; Irene Carrión-Barberà; Juan Antonio Meraz-Ostíz; Tarek Carlos Salman-Monte; Carolina Pérez-García

doi:10.1016/j.jbspin.2020.03.018

Tocilizumab may induce secondary hypogammaglobulinaemia. A retrospective case series of 42 patients

Joint Bone Spine. 2020 Oct;87(5):503-505. doi: 10.1016/j.jbspin.2020.03.018. Epub 2020 Apr 29.

Authors

Francisco Vílchez-Oya¹, Ana Pros², Irene Carrión-Barberà², Juan Antonio Meraz-Ostíz², Tarek Carlos Salman-Monte², Carolina Pérez-García²

Affiliations

¹ Department of Rheumatology, Consorci Parc de Salut MAR/Hospital del Mar., Barcelona, Spain. Electronic address: fvilchez@outlook.es.
² Department of Rheumatology, Consorci Parc de Salut MAR/Hospital del Mar., Barcelona, Spain.

PMID: 32360832
DOI: 10.1016/j.jbspin.2020.03.018

No abstract available

Keywords: Antibodies; Antibody deficiency; Autoimmune; B-cell; Cytokine; Hypogammaglobulinemia; IL-6; Interleukine-6; Monoclonal antibody; Tocilizumab.

Publication types

Letter

MeSH terms

Agammaglobulinemia* / chemically induced
Agammaglobulinemia* / diagnosis
Antibodies, Monoclonal, Humanized / adverse effects
Humans
Receptors, Interleukin-6
Retrospective Studies

Substances

Antibodies, Monoclonal, Humanized
Receptors, Interleukin-6
tocilizumab